ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,505.22
1.35%
Dow Jones
43,487.83
0.78%
Gold vs US Dollar
2,703.20
0.00%
Brent Oil
80.005
0.00%
Bitcoin
103,157.95
-0.93%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ImmunityBio Inc (IBRX)

  7. ImmunityBio Inc (IBRX) News

ImmunityBio (IBRX)

ImmunityBio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IBRX
DateTimeSourceHeadlineSymbolCompany
15/01/202522:20Business WireImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the AgencyNASDAQ:IBRXImmunityBio Inc
15/01/202522:20Business WireImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United KingdomNASDAQ:IBRXImmunityBio Inc
06/01/202514:00Business WireImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now EffectiveNASDAQ:IBRXImmunityBio Inc
03/01/202521:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
12/12/202413:00GlobeNewswire Inc.D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public OfferingNASDAQ:IBRXImmunityBio Inc
12/12/202411:45Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IBRXImmunityBio Inc
11/12/202412:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
11/12/202412:30Business WireImmunityBio, Inc. Announces Pricing of Public Offering of Common StockNASDAQ:IBRXImmunityBio Inc
10/12/202422:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
10/12/202422:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IBRXImmunityBio Inc
10/12/202421:24Business WireImmunityBio, Inc. Announces Proposed Public Offering of Common StockNASDAQ:IBRXImmunityBio Inc
21/11/202415:00PR Newswire (US)ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data FulfillmentNASDAQ:IBRXImmunityBio Inc
19/11/202414:00PR Newswire (US)ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsNASDAQ:IBRXImmunityBio Inc
19/11/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
19/11/202413:00Business WireImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 MonthsNASDAQ:IBRXImmunityBio Inc
12/11/202412:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
12/11/202412:15Business WireImmunityBio Reports Third-Quarter 2024 Financial ResultsNASDAQ:IBRXImmunityBio Inc
24/10/202413:00Business WireFirst Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin LymphomaNASDAQ:IBRXImmunityBio Inc
21/10/202413:00Business WireImmunityBio to Participate in the Jefferies London Healthcare ConferenceNASDAQ:IBRXImmunityBio Inc
09/09/202412:30Business WireImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer NASDAQ:IBRXImmunityBio Inc
12/08/202412:46Business WireImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA ApprovalNASDAQ:IBRXImmunityBio Inc
12/08/202412:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
06/08/202413:00Business WireImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial CancerNASDAQ:IBRXImmunityBio Inc
25/07/202415:02PR Newswire (US)Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law FirmNASDAQ:IBRXImmunityBio Inc
18/07/202401:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
20/06/202413:00Business WireImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint InhibitorsNASDAQ:IBRXImmunityBio Inc
13/06/202422:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
13/06/202422:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
13/06/202422:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
13/06/202422:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
 Showing the most relevant articles for your search:NASDAQ:IBRX

Your Recent History

UPBT
ZENBTC
Horizen
DOWI
DJIHCT
DJ Industrial Average To...
LSE
0DGZ
Adolfo Dominguez
BOV
BFEM39
First Trust Global Funds
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads